Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis-Reference-Cited by-同舟云学术

Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis

Published:2023-12-21 Issue:25 Volume:142 Page:2216-2219
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Russler-Germain David A.¹²^ORCID,Cliff Edward R. Scheffer³⁴^ORCID,Bartlett Nancy L.¹²^ORCID

Affiliation:

1. 1Division of Oncology, Washington University School of Medicine, St. Louis, MO

2. 2Siteman Cancer Center, St. Louis, MO

3. 3Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA

4. 4Harvard Medical School, Boston, MA

Abstract

Abstract Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among patients with activated B-cell subtype disease. Both preclinical and additional clinical evidence support this interaction between cell-of-origin and polatuzumab efficacy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/142/25/2216/2177487/blood_bld-2023-022048-main.pdf

Reference25 articles.

1. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma;Tilly;N Engl J Med,2022

2. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;Alizadeh;Nature,2000

3. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL;Wilson;Cancer Cell,2021

4. Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin;Palmer;N Engl J Med,2023

5. Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials;Wallach;JAMA Intern Med,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Analysis of histologic, immunohistochemical and genomic features of large B cell lymphoma tumors may predict response to polatuzumab vedotin based therapy in patients with relapsed/refractory disease;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-07-03

4. A mechanistic model of curative combination therapy explains lymphoma clinical trial results;2024-06-25

5. Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome;Cancers;2024-06-07